ClinicalTrials.gg
Status unknownNCT05666011Updated Mar 20, 2023

Laser to Aid in Treatment of Keratosis Pilaris on Arms

An interventional study of M22 IPL in Keratosis Pilaris, sponsored by Goldman, Butterwick, Fitzpatrick and Groff. Status unknown. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by Goldman, Butterwick, Fitzpatrick and Groff · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess efficacy and safety of intense pulsed light (IPL) activation of silver nanoparticles (SNA) versus IPL alone for treatment of keratosis pilaris.

Read the detailed description

The primary objective of this pilot study is to assess efficacy and safety of intense pulsed light (IPL; StellarM22™ Universal IPL, Lumenis Ltd., Yokneam, Israel) alone versus combination of IPL activation of silver nanoparticles (SNA) for treatment of keratosis pilaris.

Prior to first treatment, right and left arms of 10 enrolled subjects will be randomized to combination treatment with IPL activation of SNA (i.e. intervention arm) versus IPL alone (i.e. control arm). The intervention arm will be pre-treated with sugaring to epilate existing hair. This arm will then be treated with 0.5mL of nanoparticle suspension administered with a standard infusion paddle for 5 minutes prior to IPL treatment.

Following nanoparticle infusion, excess suspension will be removed from the surface of the skin with a pre-moistened wipe. Once all visible suspension is removed from the skin, the area will be cleansed with an alcohol wipe. If the alcohol wipe shows that the suspension is still present on the surface of the skin, additional pre-moistened wipes will be used to cleanse the skin until the alcohol wipe comes away without visible suspension. IPL will then be applied to the intervention arm.

Treatments will be repeated three times, spaced four- to six-weeks apart. After completing all three treatments, patients will return for macroscopic and dermoscopic photography at 1 month and 3 months.

02

Conditions studied

  • Keratosis Pilaris

Keywords

  • keratosis pilaris
  • arms
03

In context

Lead sponsor

Goldman, Butterwick, Fitzpatrick and Groff is the lead sponsor of 41 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and females aged 18 or older with clinical diagnosis of KP of the posterior upper arms.
  • Subjects in good general health based on investigator's judgment and medical history
  • Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study
  • Understands and accepts the obligation and is logistically able to be present for all visits
  • Is willing to comply with all requirements of the study and sign the documents
  • Must be willing to maintain usual sun exposure for the duration of the study
  • Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study
  • Subject agrees to avoid any changes in current skincare regimen.
  • Negative urine pregnancy test result at the time of study entry (if applicable)
  • For female subjects of , must be willing to use an acceptable form of during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.

    1. A female is considered of childbearing potential unless she is , without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
    2. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and/or vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study
  • The subject is hypersensitive to light in the visible and/or near infrared wavelength region
  • The subject is taking medication which is known to increase sensitivity to sunlight
  • The subject has a seizure disorder triggered by light
  • The subject has a pacemaker
  • The subject has a metal implant that interferes with the transmission of energy to the electrical field
  • The subject has any embedded electronic devices that give or receive a signal such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant
  • Gold or metal allergy
  • The subject has nerve insensitivity to heat in the treatment area or in the neutral pad placement area or a neuropathic disorder
  • The subject has used topical keratolytics, retinoids, chemical or mechanical exfoliative treatments in the 30 days prior to application of study treatment
  • Dermal fillers, biostimulators, laser treatments, or other energy-based light treatments during the 6-month period before study treatment
  • Subjects with tattoos in the treatment areas
  • Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study
  • Subjects with a history of or presence of any skin condition/disease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, neoplasm of uncertain behavior, or untreated keratinocyte carcinoma/melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters
  • History of keloid or hypertrophic scarring
  • Subjects with an active bacterial, viral, or fungal infection of the treatment areas
  • The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated
  • Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator
  • Presence of incompletely healed wound(s) in the treatment area
  • Current participation or participation within 30 days prior to the start of this study in a drug or other research study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Group A -- Right side is Intervention Arm, Left side is Control Arm

    Right Arm will be treated with IPL activation of SNA (Silver Nanoparticles ) and left arm with IPL alone.

    Device: M22 IPL

  • Experimental
    Group B -- Left side is Intervention Arm, Right side is Control Arm

    Left Arm will be treated with IPL activation of SNA (Silver Nanoparticles ) and right arm with IPL alone.

    Device: M22 IPL

Interventions

  • DeviceM22 IPL

    IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.

    Also known as: StellarM22 Intense Pulsed Light Laser

06

What researchers measure

Primary outcomes

  1. Erythema Grading Scale by a blinded investigator to assess change (one for each arm)

    Erythema grading scale (Right Arm) 0 No erythema 1. Mild erythema 2. Moderate erythema 3. Severe erythema 4. Very severe erythema Erythema grading scale (Left Arm) 0 No erythema 1. Mild erythema 2. Moderate erythema 3. Severe erythema 4. Very severe erythema

    Time frame: Baseline, Day 30, Day 60, Day 90, Day 110

  2. Textural Change Grading Scale by a blinded investigator (one for each arm)

    Textural change grading scale ( Right Arm) 0 No textural change 1. Mild textural change 2. Moderate textural change 3. Severe textural change 4. Very severe textural change Textural change grading scale (Left Arm) 0 No textural change 1. Mild textural change 2. Moderate textural change 3. Severe textural change 4. Very severe textural change

    Time frame: Baseline, Day 30, Day 60, Day 90, Day 110

  3. Investigator Global Aesthetic Improvement Scale (IGAIS) by a blinded investigator

    Blinded Physician Global Aesthetic Improvement Scale Rating Description 1. Very Much Improved- Optimal cosmetic result in this subject 2. Much Improved- Marked improvement in appearance form the initial condition, but not completely optimal for this subject. 3. Improved- Obvious improvement in appearance from initial condition, but a re- treatment is indicated. 4. No Change- The appearance is essentially the same as the original condition. 5. Worse- The appearance is worse than the original condition. Scores (write a number under each treated area or check "Not Treated") Right Arm Left Arm Not Treated Not Treated

    Time frame: Day 30, Day 60, Day 90, Day 110

Secondary outcomes

  1. Subject Global Aesthetic Improvement Scale (SGAIS)

    Subject Global Aesthetic Improvement Scale Assessment How would you rate the overall change in appearance of your treated areas? Non-treated areas will be checked as "Not Treated" for you. Rating Description 1. Very Much Improved- Optimal cosmetic result in this subject 2. Much Improved- Marked improvement in appearance form the initial condition, but not completely optimal for this subject. 3. Improved- Obvious improvement in appearance from initial condition, but a re-treatment is indicated. 4. No Change- The appearance is essentially the same as the original condition. 5. Worse- The appearance is worse than the original condition. Scores (write a number under each treated area or check "Not Treated") Right Arm Left Arm Not Treated Not Treated

    Time frame: Day 30, Day 60, Day 90, Day 110

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05666011
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Responsible party
Sponsor
First posted
Dec 27, 2022
Start date
Mar 20, 2023 (estimated)
Primary completion
May 30, 2023 (estimated)
Completion
May 30, 2023 (estimated)
Last update
Mar 20, 2023

Study contacts

Andrea Pacheco
Contact
apacheco@clderm.com
8586571004
Sherif Mikhail, MD
Contact
smikhail@westderm.com
8586571004

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion